ArticleOxford medical case reports2026
Paroxysmal motor signs in multiple sclerosis: an illustrative videotaped case.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) presents with a wide spectrum of neurological manifestations, among which paroxysmal motor phenomena remain a diagnostic and therapeutic challenge. We report the case of a 29-year-old male diagnosed with relapsing-remitting MS (RRMS) who exhibited episodes of paroxysmal dystonia, dysarthria-ataxia, and ptosis. Brain MRI revealed multiple demyelinating plaques, including a contrast-enhancing lesion in the right midbrain, which provides an anatomical correlation with the patient's neurological manifestation. The dystonic movements resolved with corticosteroid therapy, while symptomatic management with carbamazepine was required for dysarthria-ataxia. Ocrelizumab has been proposed as a long-term disease-modifying treatment. This case highlights the importance of recognizing paroxysmal motor signs in MS for early diagnosis and tailored management, despite their elusive pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.